Venetoclax is currently approved in Europe for the treatment of patients with relapsed/refractory CLL who have failed chemotherapy and BCR inhibitor therapy, or patients with del(17p) or TP53 mutation who are ineligible for or have failed BCR inhibitor therapy [30]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.